Literature DB >> 2163669

Level of ubiquitinated histone H2B in chromatin is coupled to ongoing transcription.

J R Davie1, L C Murphy.   

Abstract

The relationship between transcription and ubiquitination of the histones was investigated. Previous studies have shown that ubiquitinated (u) histone H2B and, to a lesser extent, mono- and polyubiquitinated histone H2A are enriched in transcriptionally active gene-enriched chromatin fractions. Here, we show that treatment of T-47D-5 human breast cancer cells with actinomycin D (10 micrograms/mL) or 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole, inhibitors of heterogeneous nuclear RNA synthesis, selectively reduced the level of uH2B, but not uH2A, uH2A.Z, or polyubiquitinated H2A, in chromatin. Treatment of the cells with low levels (0.04 micrograms/mL) of actinomycin D slightly reduced the level of uH2B, suggesting that inhibition of ribosomal RNA synthesis does not have a profound effect on the level of uH2B in chromatin. The level of the ubiquitinated histones was not affected by treating the cells with inhibitors of DNA synthesis (sodium butyrate or aphidicolin), but heat-shock treatment resulted in the loss of all the monoubiquitinated histone species. These results demonstrate that maintenance of the levels of uH2B in chromatin is dependent upon ongoing transcription, particularly the synthesis of hnRNA. Thus, histone H2B would be ubiquitinated when the nucleosome was opened during transcription. Ubiquitination of histone H2B may impede nucleosome refolding, facilitating subsequent rounds of transcription.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2163669     DOI: 10.1021/bi00472a002

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  36 in total

Review 1.  Evolutionary consequences of nonrandom damage and repair of chromatin domains.

Authors:  T Boulikas
Journal:  J Mol Evol       Date:  1992-08       Impact factor: 2.395

2.  Inhibiting eukaryotic transcription: Which compound to choose? How to evaluate its activity?

Authors:  Olivier Bensaude
Journal:  Transcription       Date:  2011-05

3.  Changes in the nuclear matrix of chicken erythrocytes that accompany maturation.

Authors:  H Y Chen; J M Sun; M J Hendzel; J B Rattner; J R Davie
Journal:  Biochem J       Date:  1996-11-15       Impact factor: 3.857

Review 4.  Nuclear matrix, dynamic histone acetylation and transcriptionally active chromatin.

Authors:  J R Davie
Journal:  Mol Biol Rep       Date:  1997-08       Impact factor: 2.316

5.  Proteomic analysis of arginine methylation sites in human cells reveals dynamic regulation during transcriptional arrest.

Authors:  Kathrine B Sylvestersen; Heiko Horn; Stephanie Jungmichel; Lars J Jensen; Michael L Nielsen
Journal:  Mol Cell Proteomics       Date:  2014-02-21       Impact factor: 5.911

6.  Concerted evolution in protists: recent homogenization of a polyubiquitin gene in Trichomonas vaginalis.

Authors:  P J Keeling; W F Doolittle
Journal:  J Mol Evol       Date:  1995-11       Impact factor: 2.395

7.  Effects of histone acetylation, ubiquitination and variants on nucleosome stability.

Authors:  W Li; S Nagaraja; G P Delcuve; M J Hendzel; J R Davie
Journal:  Biochem J       Date:  1993-12-15       Impact factor: 3.857

8.  Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8.

Authors:  Karl W Henry; Anastasia Wyce; Wan-Sheng Lo; Laura J Duggan; N C Tolga Emre; Cheng-Fu Kao; Lorraine Pillus; Ali Shilatifard; Mary Ann Osley; Shelley L Berger
Journal:  Genes Dev       Date:  2003-10-16       Impact factor: 11.361

9.  Repetitious structure and transcription control of a polyubiquitin gene in Volvox carteri.

Authors:  B Schiedlmeier; R Schmitt
Journal:  Curr Genet       Date:  1994-02       Impact factor: 3.886

10.  CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3'-end processing.

Authors:  Judith Pirngruber; Andrei Shchebet; Lisa Schreiber; Efrat Shema; Neri Minsky; Rob D Chapman; Dirk Eick; Yael Aylon; Moshe Oren; Steven A Johnsen
Journal:  EMBO Rep       Date:  2009-07-03       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.